로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IL-35 R

IL-35 R

요약

Name:Interleukin-6 receptor subunit beta
Target Synonym:IL6ST,Oncostatin-M Receptor Subunit Alpha,CD130,Interleukin-6 Signal Transducer,Interleukin-6 Receptor Subunit Beta,Gp130 Of The Rheumatoid Arthritis Antigenic Peptide-Bearing Soluble Form,CD130 Antigen,Membrane Glycoprotein Gp130,SGP130,IL-6R-Beta,HIES4,Gp130, Oncostatin M Receptor,IL-6RB,GP130,Cytokine Receptor gp130,Interleukin 6 Signal Transducer,Membrane Glycoprotein 130,Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor),CDW130,IL-6 Receptor Subunit Beta,Interleukin Receptor Bet
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
ILR-H52H8 Human Human IL-35 R / gp130 & IL12Rb2 Protein, His Tag (MALS verified)
ILR-H52H8-sds

일부의 생물활성 데이터

ILR-H52H8-MALS-HPLC
IL-35 R MALS images

The purity of Human IL-35 R, His Tag (Cat. No. ILR-H52H8) is more than 90% and the molecular weight of this protein is around 185-215 Kda verified by SEC-MALS.

ILR-H52H8-ELISA
 IL-35 R ELISA

Immobilized Human IL-35 R, His Tag (Cat. No. ILR-H52H8) at 5 μg/mL (100 μL/well) can bind Human IL-35, Fc Tag (Cat. No. IL5-H5259) with a linear range of 0.002-0.625 μg/mL (QC tested).

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocilizumab rhPM-1; RO-48775533; RG-1569; MRA; HPM-1; MRA-SC; R-1569 Approved Chugai Pharmaceutical Co Ltd Actemra, RoActemra, 雅美罗, Actemra/RoActemra, Acterma Japan Arthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD) null 2005-04-11 Lymphoma; Graves Ophthalmopathy; Ascites; Takayasu Arteritis; Pancreatitis, Chronic; Coronavirus Infections; Pulmonary Arterial Hypertension; Coronary Disease; Lupus Erythematosus, Systemic; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Multicentric Castleman's Disease (MCD); Fever; Uveitis, Posterior; Stroke; Pulmonary Disease, Chronic Obstructive; Osteoarthritis; Uveitis; Rejection in heart transplantation; Inflammation; Pleural Effusion, Malignant; Panuveitis; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Anemia, Sickle Cell; Carcinoma, Hepatocellular; Non-ST Elevated Myocardial Infarction; Myocardial Infarction; Hematologic Neoplasms; Solid tumours; Cytokine Release Syndrome; Motor Neuron Disease; HIV Infections; Diabetes Mellitus, Type 1; Acute Chest Syndrome; Craniopharyngioma; Polymyositis; Giant Cell Arteritis; Schnitzler Syndrome; Depressive Disorder, Major; Polyarticular Juvenile Idiopathic Arthritis; Non-radiographic axial spondyloarthritis; Uveitis Details
Tocilizumab biosimilar (Bio-Thera Solutions) BAT-1806; BIIB-800 Approved Bio-Thera Solutions Ltd 施瑞立, TOFIDENCE Mainland China Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome Bio-Thera Solutions Ltd 2023-01-16 Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile Details
Sarilumab SAR-153191; REGN-88 Approved Sanofi, Regeneron Pharmaceuticals Inc Kevzara United States Arthritis, Rheumatoid Sanofi-Synthelabo 2017-05-22 Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Sarcoidosis; Arthritis, Juvenile; Polymyalgia Rheumatica; Severe Acute Respiratory Syndrome; Uveitis Details
Tocilizumab biosimilar (Livzon Group) LZM-008 Approved Livzon Pharmaceutical Group Inc 安维泰 Mainland China Arthritis, Rheumatoid Livzon Mabpharm Inc 2023-01-18 Arthritis, Rheumatoid Details
Tocilizumab biosimilar (Fresenius kabi) MSB-11456; AT-220 (Arecor Therapeutics) Approved Merck Serono Tyenne EU Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis Fresenius Kabi Deutschland Gmbh 2023-09-15 Cytokine Release Syndrome; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) Details
Tocilizumab biosimilar (BioRay Pharm) Approved Hisun Biopharmaceutical Co Ltd Mainland China Arthritis, Rheumatoid Hisun Biopharmaceutical Co Ltd 2024-06-25 Arthritis, Rheumatoid Details
Tocilizumab biosimilar (Celltrion) CT-P47; CT-P-47 Approved Celltrion Inc Avtozma United States Arthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Coronavirus Disease 2019 (COVID-19) Celltrion Inc 2025-01-24 Giant Cell Arteritis; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis, Juvenile Details
Tocilizumab biosimilar (Maibo Taike) CMAB-806; CMAB806 Approved Taizhou Maibo Taike Biotechnology Co Ltd, Jinyu Bowo Runze Biotechnology Co Ltd Mainland China Arthritis, Rheumatoid Jinyu Bowo Runze Biotechnology Co Ltd 2024-10-16 Arthritis, Rheumatoid; Arthritis Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) HS-628 Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Arthritis, Rheumatoid; Arthritis Details
VDJ-001 Phase 3 Clinical Beijing Vdjbio Co Ltd Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) Details
Tocilizumab Biosimilar (Curateq Biologics) BP08; BP-08 Phase 3 Clinical CuraTeQ Biologics Pvt Ltd Arthritis, Rheumatoid Details
Tocilizumab biosimilar (GENERIUM Pharmaceuticals) GNR-087 Phase 3 Clinical Generium Pharmaceuticals Arthritis, Rheumatoid Details
Tocilizumab biosimilar (AryoGen Pharmed) Phase 3 Clinical Aryogen Biopharma Arthritis, Rheumatoid Details
Tocilizumab biosimilar(Hetero Biopharma) Phase 3 Clinical Hetero Biopharma Ltd Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid Details
Levilimab BCD-089 Phase 3 Clinical BIOCAD JSC Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid Details
Olamkicept FE-999301; CR-5/18; TJ-301; FE-301 Phase 2 Clinical Conaris Research Institute Gastrointestinal Diseases; Colitis, Ulcerative Details
Atexakin alfa SON-080; r-IL-6 Phase 2 Clinical Weizmann Institute Of Science Peripheral Nervous System Diseases; Diabetic Neuropathies Details
Tocilizumab Biosimilar (qyuns) QX-003-S Phase 1 Clinical Qyuns Therapeutics Co Ltd Arthritis, Rheumatoid Details

This web search service is supported by Google Inc.

totop